{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":14,"youtube":3,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03534804\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PemCab","nct_id":"NCT03534804","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pemcab-nct03534804. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PemCab","arms":[{"description":null,"label":"Cabozantinib and Pembrolizumab, all patients","type":"EXPERIMENTAL"}],"collaborators":["Exelixis"],"completion_date":{"date":"2024-04-15","type":"ACTUAL"},"conditions":["Metastatic Urothelial Carcinoma","Bladder Cancer"],"enrollment":{"count":37,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cabozantinib","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2024-11-26","lead_sponsor":"University of Utah","official_title":"Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-08-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Count of Participants With Response Measured by RECIST 1.1","timeFrame":"From baseline disease assessment to best response disease assessment, measured up to 28 months."}],"references":[],"start_date":{"date":"2018-09-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma","url":"https://clinicaltrials.gov/study/NCT03534804"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pemcab-nct03534804"}